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Neurotransmittersa b s t r a c t
Neuronal communication plays an essential role in the propagation of information in the brain and
requires a precisely orchestrated connectivity between neurons. Synaptic transmission is the mech-
anism through which neurons communicate with each other. It is a strictly regulated process which
involves membrane depolarization, the cellular exocytosis machinery, neurotransmitter release
from synaptic vesicles into the synaptic cleft, and the interaction between ion channels, G
protein-coupled receptors (GPCRs), and downstream effector molecules. The focus of this review
is to explore the role of GPCRs and G protein-signaling in neurotransmission, to highlight the func-
tion of GPCRs, which are localized in both presynaptic and postsynaptic membrane terminals, in reg-
ulation of intrasynaptic and intersynaptic communication, and to discuss the involvement of
astrocytic GPCRs in the regulation of neuronal communication.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction serotonin; (3) the neuropeptides; and (4) theEfﬁcient neuronal communication is crucial for sensory percep-
tion, stimulus transduction, information processing, and motor
output in every vertebrate animal. This process requires a
well-deﬁned connection between neurons to ensure the integra-
tion of both external and internal sensory input and the generation
of appropriate responses to meet the demands of the individual’s
environment [1]. Neurons communicate with each other through
two principal mechanisms: the secretion of chemical messengers
called neurotransmitters at chemical synapses and the direct
transfer of intercellular signals via gap junctions at electrical
synapses [2]. Electrical coupling between neurons is very rare in
the vertebrate central nervous system (CNS). Therefore, most neu-
ronal communication in vertebrate systems depends on the release
of a wide variety of neurotransmitters, which can be divided into
four classes: (1) the classical neurotransmitters glutamate,
c-aminobutyric acid (GABA), glycine, acetylcholine, adenosine,
and adenosine-triphosphate (ATP); (2) the monoaminergic neuro-
transmitters dopamine, noradrenaline, adrenaline, histamine, andmembrane-permeable mediators nitric oxide, endocannabinoids,
and other gaseous and lipidic neurotransmitters [2]. The classical
neurotransmitters are released by calcium (Ca2+)-triggered exocy-
tosis, allowing rapid neuronal communication. The monoaminergic
neurotransmitters are also released by Ca2+-dependent exocytosis
from axon terminals, but these neurotransmitters can diffuse over
longer distances and have moderate to fast signaling kinetics. The
neuropeptides undergo Ca2+-dependent exocytosis, are not
restricted to certain neuronal structures, and can diffuse over very
long distances with long-lasting effects. In contrast, the membrane
permeable mediators are released immediately after synthesis and
are not stored in vesicles. The signaling duration and range of dif-
fusion are both short. Collectively, chemical synapses consist of
distinct types of vesicles, which differ in their morphology, release
kinetics, and distribution; however, the cellular machinery is con-
served for fusion events and requires Ca2+-mediated exocytosis [3].
The released neurotransmitters bind to and activate receptors
on postsynaptic membranes. Neurotransmitter-gated ion channels,
or ionotropic receptors, are responsible for fast synaptic transmis-
sion [4]. These receptors are located close to the neurotransmitter
release site and decode chemical signals into electrical responses in
postsynaptic neurons. Slow synaptic transmission is mediated by
GPCRs [5]. These receptors are indirectly linked to ion channels
and may also be distally located relative to the neurotransmitter
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with multiple downstream effectors. Many nerve terminals, such
as sympathetic axons, auditory giant synapses, and hippocampal
mossy ﬁbers, are regulated by both GPCRs and ionotropic receptors
[6]. Consequently, the actions of GPCRs and ionotropic receptors
can differ greatly with variations in receptor afﬁnity, activation
and desensitization properties determining the effect at a given
synaptic terminal (see Fig. 1).
GPCRs are the largest family of membrane proteins. More than
800 GPCRs have been identiﬁed in the human genome, including
over 370 non-sensory GPCRs. More than 90% of these GPCRs are
expressed in the brain, where they play important roles in cogni-
tion, mood, appetite, pain, and synaptic transmission through
presynaptic and postsynaptic modulation of neurotransmitter
release [7]. GPCR ligands include a wide range of molecules such
as photons, ions, biogenic amines, peptide and non-peptide neuro-
transmitters, hormones, growth factors, and lipids [8]. Accordingly,
GPCRs are involved in various physiological functions including
vision, taste, olfaction, sympathetic and parasympathetic nervous
functions, metabolism, and immune regulation and are important
therapeutic targets in many human diseases including diabetes,
neurodegeneration, cardiovascular disease, and psychiatric disor-
ders [9–11]. Based on sequence and structural similarities, GPCRs
are phylogenetically classiﬁed into ﬁve main families: Rhodopsin
(701 members), Glutamate (15 members), Adhesion (24 members),
Frizzled/Taste2 (24 members), and Secretin (15 members), with
each family exhibiting unique ligand binding properties [12,13].
All GPCRs are characterized by the presence of seven
transmembrane-spanning a-helical segments separated by alter-
nating intracellular and extracellular loop regions [14]. Despite
these similarities, individual GPCRs display unique combinations


















Fig. 1. Neuronal and astrocytic GPCRs modulate glutamatergic neurotransmission. Astr
System N (SN1) transporters. Glutamine is then taken up by neurons at presynaptic mem
glutamate. Glutamate is then packaged into synaptic vesicles prior to release in the syna
fusion and release. The process is regulated by the GPCR-mediated activation of G
intracellular Ca2+ stores. In the synaptic cleft, glutamate binds to activated NMDARs or
currents (EPSCs). Certain activated GPCRs mediate the release of Ca2+ from intracellular C
of GPCRs may also lead to gene transcription and the modulation of synaptic plasticity
regulates glutamate uptake by astrocytes. Glutamate can also be released directly from
activation of certain GPCRs.subtypes as well as G protein-independent signaling pathways.
Recent breakthrough developments in protein engineering and
crystallography studies have begun to elucidate the structural
basis by which this is accomplished and have provided signiﬁcant
insight into how protein structure dictates the unique functional
properties of these complex signaling molecules [14,15]. For most
GPCRs, binding of the endogenous hormone or neurotransmitter
promotes a conformational change that results in the activation
of receptor-associated heterotrimeric G proteins and consequent
downstream signaling [14]. Heterotrimeric G proteins are com-
posed of three subunits, a, b and c. Ligand binding catalyzes the
exchange of bound guanosine diphosphate (GDP) on the Ga sub-
unit for guanosine triphosphate (GTP). The exchange in the gua-
nine nucleotides leads to a reduction in the afﬁnity of the Ga
subunit for the Gbc complex and functional dissociation of the het-
erotrimer [16]. The dissociated G protein subunits can then trans-
mit signals to effector proteins, such as enzymes and ion channels,
resulting in rapid changes in the concentration of intracellular sig-
naling molecules, cyclic adenosine monophosphate (cAMP), cyclic
guanosine monophosphate (cGMP), inositol phosphates, diacyl-
glycerol, arachidonic acid, and cytosolic ions, which affect a variety
of cellular functions [17]. The focus of this review is to discuss the
regulation of neuronal communication at the synapse by GPCR sig-
naling pathways.
2. Neuronal GPCRs
2.1. Metabotropic glutamate receptors (mGluRs)
Glutamate belongs to the ﬁrst class of classical neurotransmit-
ters. It functions as the major excitatory neurotransmitter in the







System A transporter 
Ion channel
ocytes produce glutamine, which can be directly secreted from astrocytes through
brane terminals by system A transporter (SA1 and SA2) inﬂux for the synthesis of
ptic cleft. Elevation of presynaptic intracellular Ca2+ levels triggers synaptic vesicle
protein-signaling cascades which promotes/inhibits Ca2+ inﬂux or the release of
AMPARs, resulting in a Ca2+ inﬂux and the induction of fast excitatory postsynaptic
a2+ stores to increase of intracellular Ca2+ levels, which evoke slow EPSCs. Activation
. Astrocytic GPCRs can modulate sodium-dependent glutamate transporters which
astrocytes via ion channels, such as TREK-1 and Best1, which are involved in the
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porter (SN1) efﬂux [18] to neurons by system A transporter (SA1
and SA2) inﬂux for the synthesis of glutamate. Glutamate released
from presynaptic terminals, binds to postsynaptic glutamate
receptors, which are involved in the modulation of neuronal exci-
tation. Interestingly, the lipid mediator sphingosine 1-phosphate
(S1P) has been shown to induce and potentiate glutamate release
from presynaptic terminals [19]. Two categories of glutamate
receptors have been indentiﬁed: ionotropic glutamate receptors
and metabotropic glutamate receptors. Ionotropic glutamate
receptors include four classes of receptors: the
N-methyl-D-aspartate (NMDA), a-amino-3-hydroxy-5-methyl-4-i
soxazolepropionic acid (AMPA), Delta, and kainate receptors,
which function as ion channels and trigger postsynaptic currents
upon glutamate-mediated synaptic activation. In contrast,
mGluRs are a group of GPCRs which initiate G protein-signaling
cascades following receptor activation. Eight different types of
mGluRs have been identiﬁed in humans. Based on their structure
and physiological activity, they have been divided into three
groups: group I (mGluR1 and mGluR5), group II (mGluR2 and
mGluR3), and group III (mGluR4, mGluR6, mGluR7 and mGluR8).
The three groups of mGluRs are highly expressed in the neocortical
layers, hippocampus, basal ganglia, thalamus/hypothalamus, cere-
bellum and spinal cord; however, mGluR6 expression is restricted
to the visual sensory system in retinal rod bipolar cells [20].
Subcellularly, group I mGluRs are predominantly localized in post-
synaptic membrane terminals where they mainly activate Gq sig-
naling. Nevertheless, group I mGluRs have also been shown to be
localized in presynaptic terminals in the lamprey spinal cord
where they promote neurotransmitter release and control motor
function [21].
Activation of postsynaptic mGluR1s stimulated Gaq-mediated
Ca2+ release from Ca2+ stores in the endoplasmic reticulum (ER)
has been shown to lead to long-term depression (LTD) in cerebellar
slices from rats and mice [22]. Further studies indicate that genetic
deletion of mGluR1 results in deﬁcient cerebellar LTD and ataxia
[23]. Correlative evidence also suggests that the loss of Gq signal-
ing, which involves reduced protein kinase C (PKC) and phospholi-
pase C-b-4 (PLCb4) activity and inositol 1,4,5 trisphosphate
(IP3)-mediated release of intracellular Ca2+ ER stores from cerebel-
lar Purkinje cells results in the ataxic behavior [24–28]. Given that
cerebellar damage has been associated with the ataxia phenotype
[29], these studies suggest that mGluR1-mediated LTD is crucial
for the maintenance of cerebellar function.
Activation of the mGluR1s also generates slow excitatory post-
synaptic potentials (sEPSPs). This effect is mediated by the tran-
sient receptor potential channel 3 (TRPC3) [30], a non-selective
channel permeable to Ca2+, sodium (Na+) and other cations [31].
A recent study indicates that the function of TRPC3 is dependent
on intracellular Ca2+ levels and is regulated by the stromal interac-
tion molecule 1 (STIM1) [32], which primarily localizes to ER mem-
branes [33,34]. The putative link between TRPC3-mediated sEPSPs
and the ataxic phenotype in mGluR1 knockout (KO) mice remains
unclear. However, it has been reported that induction of LTD
requires a transient Ca2+ elevation in dendrites [35], which could
be due to TRPC3-mediated Ca2+ permeabilization, suggesting the
involvement of TRPC3 in the regulation of LTD.
In contrast to group I mGluRs, group II mGluRs are predomi-
nantly localized in presynaptic membrane terminals. Activation
of presynaptic group II mGluRs with the selective group II mGluR
agonists LY354740 or (2S,20R,30R)-2-(20,30-dicarboxycyclopropyl)
glycine (DCG-IV) has been reported to inhibit EPSCs [36,37] and
induce LTD [38]. Indeed, treatment with LY354740 induces
anxiolytic-like behavior in mice as determined by the elevated plus
maze behavioral paradigm [39]. In contrast, the anxiolytic-like
activity is absent in mGluR2 and mGluR3 KO mice treated withLY354740, indicating that activation of both receptors contribute
to the anxiolytic-like actions of mGluR2/3 agonists. The elevated
plus maze test is widely used to evaluate anxiety-associated brain
regions including limbic regions, hippocampus, amygdala, dorsal
raphe nucleus, which could be controlled by various neurotrans-
mitters, such as glutamate and GABA [40]. It has been reported that
the activation of group II mGluRs-mediated Gai/o signaling, results
in an attenuation of the Ca2+ inﬂux and a reduction in the release of
glutamate and GABA [41]. Collectively, the evidence suggests that
group II mGluRs-mediated neurotransmission is involved in the
regulation of anxiety.
Similar to group II mGluRs, group III mGluRs couple to Gi/o pro-
teins. Due to the distribution of these receptors in both presynaptic
terminals of glutamatergic and GABAergic neurons, they modulate
both excitatory and inhibitory neurotransmission; however, the
modulatory activity depends on the brain region and/or cell-type
involved. In the rat subthalamic nucleus, activation of group III
mGluRs selectively suppresses excitatory neurotransmission but
does not have an effect on inhibitory neurotransmission [42]. In
the rat globus pallidus [43] and substantia nigra pars reticulata
[44], activation of group III mGluRs inhibits both excitatory and
inhibitory neurotransmission. In guinea pig hippocampal interneu-
rons, but not pyramidal neurons, activation of group III mGluRs by
the selective group III mGluRs agonist L(+)-2-amino-4-
phosphonobutyric acid (L-AP4) has been shown to suppress both
excitatory and inhibitory neurotransmission. L-AP4 can also
enhance glutamate release in rat entorhinal cortex [45].
Conversely, it has been shown to reduce glutamate release in the
substantia nigra [46]. This discrepancy may reﬂect
neuron-speciﬁc effects of the individual activated mGluRs in differ-
ent brain regions. Nevertheless, a better understanding of the com-
plexity mGluR function and signaling will require the development
more selective agonists and antagonists for each individual mGluR.
2.2. c-Aminobutyric acid B receptors (GABABRs)
GABA belongs to the ﬁrst class of classical neurotransmitters
and is the major inhibitory neurotransmitter in the CNS where it
plays a crucial role in the control of excitability, plasticity, and net-
work synchronization. GABA is produced in the presynaptic mem-
brane terminals of GABAergic neurons from glutamine, which is
generated in astrocytes [47]. GABA mediates inhibitory neuro-
transmission through two types of GABA receptors, GABAA recep-
tors (GABAARs) and GABABRs. Both GABAARs and GABABRs are
widely distributed in the mammalian brain and are highly
expressed in cortical, hippocampal, thalamic, basal ganglia, and
cerebellar structures [48] and are involved in numerous functions,
including epilepsy, schizophrenia, depression and anxiety [49–52].
Subcellularly, both GABABR subtypes are localized to presynaptic
and postsynaptic membrane terminals [53]. Speciﬁcally, the
GABAARs, which are ionotropic receptors, function in chloride ion
channel conductance and the induction of fast synaptic inhibition.
Unlike GABAARs, GABABRs belong to the Rhodopsin GPCR family
and mediate slow and prolonged inhibitory signals. There are
two subtypes of GABABRs, GABAB1Rs and GABAB2Rs, which are gen-
erated from one gene by different promoters. A functional GABABR
requires the formation of a GABAB1R and GABAB2R heterodimer
[54]. During receptor activation, GABA binds to the GABAB1R,
inducing heterodimerization with the GABAB2R and subsequent
GABAB2R-mediated activation of Gi/o proteins. Following activation
of Gi/o, Gbc dimers are released and bind to and inhibit
voltage-dependent calcium channels (VDCCs) to suppress Ca2+
inﬂux. In addition, Gbc dimers directly interact with the
C-terminus of the synaptosomal-associated protein 25 (SNAP25)
to limit vesicle fusion, reduce GABA release, and negatively control
GABAergic neurotransmission [55,56]. At postsynaptic terminals,
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sium (GIRK) channels, which generate a potassium (K+) ion inﬂux
and hyperpolarization of the cell membrane [57]. Gbc dimers have
been shown to bind to GIRK channels to mediate neuronal hyper-
polarization [58]. Numerous studies have also revealed that lipid
rafts, scaffold proteins, targeting motifs in the receptor, and regu-
lators of G-protein signaling (RGS) proteins also contribute to the
function of GABABRs. Collectively, this complex regulation of
GABABRs in the brain may provide opportunities for novel strate-
gies to regulate GABA-dependent inhibition in normal and dis-
eased states of the CNS.
Generation of the GABAB1R and GABAB2R KO mice has provided
signiﬁcant insight into the physiological function of these recep-
tors. GABAB1R KO mice display behavioral abnormalities such as
epilepsy, hyperalgesia, impaired memory, increased anxiety and
decreased depression [59,60]. GABAB2R KO mice display similar
behavioral deﬁcits, including epilepsy, hyperalgesia and impaired
memory [61]. Nevertheless, anxiety and depression phenotypes
have not been examined in the GABAB2R KO mice. The heteromeric
nature of native GABABRs has been further emphasized by the sub-
stantial downregulation of GABAB1R protein in GABAB2R KO mice
[61]. An analogous requirement of GABAB1R for stable expression
of GABAB2R was also observed in GABAB1R KO mice [60].
Interestingly, the remaining GABAB1R protein in GABAB2R KO neu-
rons accumulates in distinct cellular compartments in comparison
to wild-type neurons, relocating from distal neuronal sites to the
soma and proximal dendrites [61]. These studies suggest that the
association of the GABAB2R with the GABAB1R is essential for recep-
tor localization in distal processes but is probably not absolutely
necessary for signaling. Therefore, it is possible that functional
GABAB1Rs exist in neurons that naturally lack GABAB2R subunits;
however, heteromeric GABAB1/2Rs are the prevalent GABABRs in
the CNS and the majority of GABAB2R protein is normally associ-
ated with the GABAB1R.
2.3. Muscarinic acetylcholine receptors (mAChRs)
Acetylcholine (ACh) belongs to the ﬁrst class of classical neuro-
transmitters and is involved in the modulation of various brain
functions. In cholinergic neurons, choline acetyltransferase
(ChAT) transfers an acetyl group from acetyl coenzyme A to choline
which results in the generation of ACh [62]. The newly synthesized
ACh is then transported into vesicles by the vesicular ACh trans-
porter (VAChT). Release of ACh activates two types of receptors:
muscarinic ACh receptors (mAChRs) and nicotinic ACh receptors
(nAChRs). MAChRs are GPCRs while nAChRs are ligand-gated
cation channels. In the current review, we will focus the discussion
on the function of the mAChRs in neurotransmission.
There are ﬁve subtypes of the mAChR family, the muscarinic
acetylcholine receptors 1–5 (M1R–M5R). Most mAChRs, except
the M5Rs, are differentially expressed in various brain regions
[63]. The M1Rs are highly expressed in the cerebral cortex, hip-
pocampus and corpus striatum and are predominantly localized
to brain regions that regulate memory consolidation. In the cortex,
the M1R is localized in layers II–VI of the cortex [64]. In the hip-
pocampus, the M1R is expressed in the CA1 and dentate gyrus
[65]. In the striatum, the M1R is found in the perikarya and in med-
ium spiny neurons [66]. In neurons, the M1R is expressed in both
presynaptic and postsynaptic membrane terminals [65]. The M1R
preferentially couples to the G protein Gaq, resulting in increase
in intracellular Ca2+ levels, which facilitates presynaptic ACh
release. In contrast, inhibition of presynaptic M1Rs with an
M1R-selective antagonist reduces ACh release from presynaptic
terminals [67]. Activation of postsynaptic M1Rs by ACh elevates
intracellular Ca2+ levels and leads to slow postsynaptic depolariza-
tion and an increase in neuronal excitability. The M1R has alsobeen shown to be involved the regulation of synaptic transmission
and neuronal excitation through inhibition of K+ channels [68,69].
Pharmacological studies using the non-selective mAChRs agonist
carbachol has been shown to induce long-term potentiation (LTP)
of excitatory synaptic transmission in mouse hippocampal slices
[70]. The effect is abolished in M1R KO mice [70], and in fact, these
mice display a mild reduction in hippocampal LTP [71].
Interestingly, studies with the M1R KO mice suggest that the
M1R is not necessary for hippocampus-dependent learning and
memory [72]; however, M1R KO mice display an impairment in
working memory and consolidation in the win-shift radial arm
and social discrimination behavioral paradigms [71]. These tests
evaluate hippocampal-dependent functions and are consistent
with changes in LTP determined by genetic and pharmacological
modulation of the M1R. Interestingly, M1R KO mice display a pro-
nounced increase in locomotor activity [73], indicating an effect on
the striatum, a region of the brain that is important for motor con-
trol [74]. In this regard, activation [75] or inhibition [76] of the
M1R represent potential approaches in the treatment of
Alzheimer’s and Parkinson’s disease, respectively.
The M2Rs are predominantly expressed in thalamus, hypothala-
mus, midbrain, pons-medulla and cerebellum. The M4Rs are
expressed in the cortex, corpus striatum, hippocampus, thalamus,
hypothalamus, pons-medulla and cerebellum. Subcellularly, the
M2R is expressed in the somatodendritic compartment, postsynap-
tic terminals, and presynaptic terminals in cholinergic neurons
[77]. In striatal neurons, the M4R is preferentially expressed in
the plasma membrane of perikarya and dendrites of medium spiny
neurons [78]. Unlike the M1R, the M2R and M4R couple to Gi/o pro-
teins to inhibit neuronal excitation. The M2R andM4R are localized
to both presynaptic and postsynaptic terminals. M4R, but not M2R,
KO mice show increased basal ACh release in the hippocampus.
ACh release is further elevated in M2R and M4R double KO mice
relative to M4R KO mice alone [79]. These studies were conﬁrmed
with the non-selective muscarinic antagonist scopolamine and the
M2/M4 antagonist AF-DX384, which induce ACh release in the hip-
pocampus [80]. Interestingly, the antagonist-induced ACh release
can be attenuated by M2R antisense treatment or in M2R KO mice
but not with M4 antisense treatment or in M4R KO mice [79,80].
Given that the M2Rs, but not the M4Rs, are highly expressed in
hippocampus, these results suggest that low expression of the
M4Rs in the hippocampus may interfere with the M2R modulation
of basal ACh levels. Conversely, the M2R may predominantly inhi-
bit ACh release in the hippocampus and cerebral cortex while the
M4R mediates ACh release in the striatum [81]. The
M2R-mediated neurotransmitter release is modulated by Gbc
dimers released from Gi/o proteins, which inhibit N-type Ca2+ chan-
nels and Ca2+ inﬂux [57]. The M2R-mediated neurotransmitter
release is also dependent on the voltage-sensitive function of the
M2R (see Section 3 for further discussion). Postsynaptically, activa-
tion of the M2Rs by ACh has been shown to inhibit EPSPs in CA1
pyramidal cells through the activation of Gi/o protein signaling
and GIRK channels [82]; however, there is lack of evidence to
demonstrate the function of postsynaptic M4Rs during
neurotransmission.
The M3Rs are expressed at relatively low levels in the cortex,
corpus striatum, hippocampus, thalamus, hypothalamus, midbrain,
and pons-medulla. The M3R is expressed in presynaptic membrane
terminals, somata and postsynaptic membrane terminals [64]. The
role of the M3Rs in neurotransmission is largely unknown. Given
that the M3R is the major mAChR involved in smooth muscle con-
traction, the M3R KO mice display stomach fundus, urinary blad-
der, and trachea problems [83]. As a result of the anatomical
distribution of the M3R receptor in presynaptic and postsynaptic
membrane terminals, a functional role for the M3Rs in neurotrans-
mission cannot be excluded; however, given the absence of a
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suggests a possible redundancy of M3R function with other
mAChRs.
2.4. Adenosine receptors (ARs)
Adenosine is a purine nucleoside, which is essential in nucleic
acid and ATP synthesis. In peripheral tissues, adenosine can be
released in response to various stress-related conditions including
inﬂammation, hypoxia, and tissue damage [84,85]. Although ade-
nosine is not a neurotransmitter, adenosine acts as a neuromodu-
lator in the CNS to regulate neuronal excitability and the release of
a wide range of neurotransmitters including glutamate, GABA,
acetylcholine and dopamine [86]. The effects of adenosine are
mediated by the adenosine receptors (ARs), A1R, A2AR, A2BR and
A3R, which all belong to the GPCR family.
The A1Rs are highly expressed in the brain in the cortex, hip-
pocampus, and cerebellum, speciﬁcally in neurons and glia, includ-
ing microglia and astrocytes [87]. In hippocampal neurons, the
A1Rs are expressed in both presynaptic and postsynaptic mem-
brane terminals [88]. The A1Rs couple to Gi/o proteins to regulate
inhibitory synaptic transmission [89]. Activation of presynaptic
Gai/o-coupled A1Rs negatively regulates adenylyl cyclase activity,
cAMP accumulation and activation of protein kinase A (PKA),
which leads to an induction of LTD [90]. Concurrently, the released
Gbc dimers inhibit P/Q-type and N-type Ca2+ channels and reduce
presynaptic Ca2+ inﬂux [91], which results in a reduction in gluta-
mate release in presynaptic terminals, glutamate-mediated NMDA
activation in postsynaptic terminals and EPSCs [92,93]. Stimulation
of postsynaptic A1Rs has been shown to result in Gbc dimer bind-
ing to and activation of GIRK channels, which leads to a reduction
in excitation in postsynaptic terminals [57,58,94]. In contrast, elec-
trophysiology studies conducted in hippocampal slices indicate
that A1R KO mice display normal LTP and LTD, but exhibit a drastic
reduction in paired pulse facilitation [72], suggesting an essential
role of the A1R in the presynaptic terminal and short-term synaptic
plasticity. Consistent with the observations on LTP and LTD, the
A1R KO mice show normal learning and memory in Morris water
maze behavioral paradigm [72,95]; however, these mice display
hyperalgesia, anxiety and emotional instability [95–97]. Further
investigation is required to understand whether these phenotypes
are due to a presynaptic or postsynaptic defect in the absence of
the A1R.
The A2ARs are mainly expressed in the striatum with lower
levels of expression observed in the cortex and hippocampus
[98]. Speciﬁcally, the A2ARs are highly expressed in postsynaptic
terminals in striatal neurons and presynaptic terminals in hip-
pocampal neurons [99]. In contrast, the A2BRs are highly expressed
in peripheral tissues with a very low expression levels throughout
the brain [98]. Unlike the A1R, the A2ARs couple to Gs proteins, and
the A2BRs couple to both Gs and Gq. Activation of the A2ARs or A2BRs
leads to an increase in cAMP accumulation and the activation of
PKA and PKC, respectively, resulting in the facilitation of neuro-
transmission [100,101]. Stimulation of the A2ARs leads to an
increase glutamate release from presynaptic terminals [102],
which could be due to the activation of Gas- or Gaq-dependent sig-
naling cascades [100,101]. The released glutamate then binds to
postsynaptic NMDA receptors (NMDARs) to promote postsynaptic
excitation and LTP [103,104]. The A2AR speciﬁc agonist CGS 21680
has been shown to facilitate synaptic neurotransmission through
PKA and PKC in hippocampal slices [105]. Conversely, acute treat-
ment of rats hippocampal slices with the A2AR selective antagonist
SCH 58261 or chronic treatment of rats with the A2AR selective
antagonist KW-6002 inhibits LTP [106,107]. In contrast to the
pharmacological studies, A2AR KO mice display an improvement
in spatial recognition memory [108] and working memory [109].These in vivo ﬁndings are especially intriguing in light of ﬁndings
that LTP is impaired in neostriatal slices from A2AR KO mice
[110]. These results are consistent with the observation that
brain-derived neurotrophic factor (BDNF) levels, which has been
shown to induce LTP [111], are reduced in the hippocampus of
A2AR KO mice [112]. Interestingly, studies have also shown that
the A1Rs and A2ARs form heterodimers that are involved in modu-
lation neurotransmission with stimulation of the A2ARs leading to a
decrease in agonist afﬁnity for the A1Rs [113]. Although the A2BRs
are expressed at low levels in comparison to the A2AR in the hip-
pocampus, this receptor has also been shown to regulate
A1R-mediated inhibition of synaptic transmission [114].
The A3Rs are highly expressed in peripheral tissues with a very
low expression throughout the brain [91]. Although the A3Rs cou-
ple to Gi/o proteins and are present in both presynaptic and postsy-
naptic terminals, the role of A3Rs in synaptic transmission remains
to be elucidated. Studies utilizing a non-selective agonist, 2-chlor
o-N6-(3-iodobenzyl)-adenosine-50-N-methyluronamide
(CI-IB-MECA) [86], which also binds to A1Rs, has not provided con-
clusive evidence for the functional role of the A3Rs in neurotrans-
mission. Nevertheless, recent studies with A3R KO hippocampal
brain slices and the selective A3R antagonist MRS1523 indicate that
the chemokine fractalkine (CX3CL1) inhibits hippocampal LTP
through A3R activity [115,116], suggesting a putative role for the
A3R in the modulation of synaptic activity. Collectively, these stud-
ies suggest that regulation of synaptic neurotransmission by the
ARs is extremely complex and involves an exquisite ﬁne tuning
of the activation and/or inhibition of AR subtypes.
2.5. 5-Hydroxytryptamine receptors (5-HTRs)
Serotonin or 5-HT is a monoamine neurotransmitter, which reg-
ulates various physiological functions. In the brain, serotonin is
produced in serotonergic neurons which are mainly localized to
the raphe nuclei in the midline of the brainstem [117].
Serotonergic neurons project to various brain regions including
the cortex, hippocampus, midbrain and hindbrain, generating in
a vast serotonin network throughout the brain. Accordingly, the
serotonin network modulates numerous and widespread physio-
logical functions including perception, motor control, memory,
aggression, addiction, and fear [117]. The regulation of serotonin
signaling is mediated by 14 serotonin receptors (Table 1), which
are classiﬁed into 7 families, 5-HT1-7 receptor (5-HT1-7R). Most of
the 5-HTRs are GPCRs with the exception of the 5-HT3Rs, which
are ligand-gated cation channels. In neurons, the 5-HTRs are
mainly localized in postsynaptic terminals; however, some
5-HTRs, such as 5-HT1AR, 5-HT2AR and 5-HT4R, are also expressed
in presynaptic terminals [118]. Consequently, individual neurons
may express multiple 5-HTRs with differential effects on neuro-
transmission. For example, layer V pyramidal neurons express
5-HT1ARs and 5-HT2ARs, which exert opposing effects on pyramidal
neuron ﬁring [119]. CNS serotonergic neurons are well-positioned
to modulate the activity of a wide variety of human brain circuits,
which partially explains the pleiotropic behavioral effects of sero-
tonin [120]. A full discussion on the modulation of serotonergic
neurotransmission has been nicely reviewed elsewhere [121] and
has been summarized in Table 1. In this section, we will focus
the discussion on the role of the 5-HT1AR in neurotransmission.
Administration of 5-HT1ARs selective agonists has been shown
to disrupt memory function in mice [122] and humans [123]. In
contrast, the selective 5-HT1ARs antagonist, WAY-100635, has been
shown to prevent the cognitive deﬁcits induced by, not only
5-HT1AR stimulation but also by cholinergic or NMDAR blockade
[124]. Adminstration of the same 5-HT1AR antagonist attenuates
LTP in rat brains by in vivo electrophysiological recordings [125].
Conversely, induction of LTP is inhibited by the 5-HT1AR selective
Table 1
Neuronal GPCRs.












Gi/o Presynaptic terminal Excitatory or inhibitory [36–38,41,198]
Metabotropic glutamate
receptors (Group III)






Gi/o Presynaptic and postsynaptic terminals Excitatory or inhibitory [199]
Muscarinic acetylcholine
receptors
M1R Gq Presynaptic and postsynaptic terminals Excitatory [64–70,200,201]
M2R Gi/o Presynaptic and postsynaptic terminals Inhibitory [77,79–82]
M3R Gq Presynaptic and postsynaptic terminals N.I. [64]
M4R Gi/o Presynaptic and postsynaptic terminals Inhibitory [78–81]
M5R Gq N.I. N.I. [202]
Adenosine receptors A1R Gi/o Presynaptic and postsynaptic terminals Inhibitory [87,92]
A2AR Gs Presynaptic and postsynaptic terminals Excitatory [87,102,113,203,204]
A2BR Gs, Gq Presynaptic terminal Excitatory [87,114]
A3R Gi/o Presynaptic and postsynaptic terminals N.I. [87]
5-HT receptors 5-HT1AR Gi/o Presynaptic and postsynaptic terminals Inhibitory [118,121]
5-HT1BR Presynaptic and postsynaptic terminals [118,121]
5-HT1DR Presynaptic and postsynaptic terminals [118,121]
5-HT1ER Postsynaptic terminal [118,121]
5-HT1FR Presynaptic and postsynaptic terminals [118,121]
5-HT2AR Gq Presynaptic and postsynaptic terminals Excitatory [118,121]
5-HT2BR [118,121]
5-HT2CR [118,121]
5-HT4R Gs Presynaptic and postsynaptic terminals Excitatory [118,121]
5-HT5AR Gi/o Postsynaptic terminal Inhibitory [118,121]
5-HT5BR [118,121]
5-HT6R Gs Postsynaptic terminal Excitatory [118,121]
5-HT7R Gs Postsynaptic terminal Inhibitory [118,121]
Neuropeptide Y receptors NPY1R Gi/o Postsynaptic terminal Inhibitory [136,138]
NPY2R Gi/o Presynaptic terminal Inhibitory [136,141]
NPY4R Gi/o N.I. N.I. [136]
NPY5R Gi/o Postsynaptic terminal Inhibitory [136,205]
Cannabinoid receptors CB1R Gi/o Presynaptic and postsynaptic terminals Inhibitory [152,155,156,161]
CB2R Gi/o Presynaptic and postsynaptic terminals N.I. [153]
N.I.: no information.
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with 5-HT1AR antagonists [126,127]. The 5-HT1AR couples to Gi/o
proteins, resulting in the activation of Gai/o signaling and
decreased cAMP accumulation and PKA activity [128].
Concurrently, the released Gbc dimers activate GIRK channels,
which results in hyperpolarization and inhibition of postsynaptic
potentials [128–130]. The 5-HT1AR has also been shown to block
N-type and P-type Ca2+ channels, reducing Ca2+ inﬂux through
Gi/o signaling via Gbc dimers [131,132]. At the synapse, activation
of the 5-HT1ARs has been shown to inhibit NMDAR- and AMPA
receptor (AMPAR)-mediated postsynaptic currents in prefrontal
cortical pyramidal neurons [133,134]. This effect has been reported
to involve the inhibition of Ca2+/calmodulin-dependent kinase II
(CaMKII) activity through 5-HT1AR-stimulated Gi/o protein signal-
ing. Speciﬁcally, stimulation of Gi/o signaling suppresses
PKA-mediated CaMKII activation and the activation of
mitogen-activated protein kinase kinase/extracellular
signal-regulated kinase (MEK/ERK) signaling cascades, which regu-
late the microtubule/kinesin-based transport of NMDARs to den-
drites and AMPAR activation [133,134]. Collectively, the evidence
indicates that 5-HT1ARs impair memory function through activa-
tion of both Ga and Gbc signaling and several downstream
effectors.2.6. Neuropeptide Y receptors (NPYRs)
The Neuropeptide Y (NPY) belongs to the pancreatic polypep-
tide family which includes two additional family members: pep-
tide YY (PYY) and pancreatic polypeptide (PP) [135]. NPY is
synthesized in the ER as a large precursor protein. Following a
series of post-translational modiﬁcations and enzymatic cleav-
ages, a 36 amino acid NPY is exocytosed into the extracellular
space [136]. NPY is one of the most abundant peptides in the
brain and is concentrated within the hypothalamic arcuate
nucleus, brainstem, and anterior pituitary. It has been reported
to modulate the stress response [136]. NPY is also abundantly
expressed in the dentate gyrus where it modulates hippocampal
excitability.
Four NPY receptors NPY1R, NPY2R, NPY4R, and NPY5R have been
identiﬁed in humans. The NPY1R, NPY2R, and NPY5R are activated
by NPY and PYY, whereas the NPY4R is activated by PP [136]. All
four NPYRs are expressed in the brain. The NPY1R and NPY2R are
expressed at higher levels in the brain relative to NPY4R and
NPY5R. The hippocampus is particularly enriched in NPY and the
NPY1Rs and NPY2Rs. [137]. The NPYRs are a family of
Gi/o-coupled GPCRs, while NPY2Rs also interact with Gq. NPY1Rs
and NPY2Rs play an important role in the modulation of glutamate
Y. Huang, A. Thathiah / FEBS Letters 589 (2015) 1607–1619 1613release in the CA3 and dentate gyrus [138]. Selective activation of
both receptors has been shown to inhibit intracellular Ca2+ and
glutamate release in hippocampal presynaptic terminals [138].
This effect may be due to modulation of K+ and Ca2+ channels in
the presynaptic terminal [139,140]. Consistent with these ﬁndings,
NPY2R activation has been reported to inhibit multiple Ca2+ chan-
nels including N-type, P/Q-type, and presynaptic VDCCs, leading to
a reduction in intracellular Ca2+ levels and glutamate release
[138,141]. Given that NPY1Rs and NPY2Rs function in the inhibition
of glutamatergic neurotransmission, the absence of these receptors
may lead to an improvement in cognitive function. Currently, one
report indicates that NPY1R KO mice display a late extinction in
fear conditioning, suggesting a role for the NPY1R in memory con-
solidation [142]. However, behavioral studies indicate that the
NPY2R KO mice display learning and memory deﬁcits in the
Morris water maze [143] and object recognition behavioral para-
digms [144]. These ﬁndings potentially reﬂect the fact that the
NPY2Rs also depress GABAergic neurotransmission [145].
Alternatively, the NPY1R may partially functionally compensate
for the absence of the NPY2R in the NPY2R KO mice. Indeed, a
recent study indicates that NPY1R/NPY2R double KO mice exhibit
a strong fear conditioning phenotype, which is not observed in
the individual NPY1R or NPY2R KO mouse models [142]. This evi-
dence suggests that the NPY1R may functionally compensate for
the absence of the NPY2R and vice versa. Interestingly, conditional
inactivation of the NPY1R in NPY5R-expressing neurons in mice
leads to an increase in anxiety-related behaviors and an improve-
ment in spatial reference memory [146]. Both the NPY1Rs and
NPY5Rs have been reported to mediate the NPY-induced
anxiolytic-like activity in the elevated plus maze and open ﬁeld
tests [147]; however, NPY5R KO mice display normal function in
the elevated plus maze and open ﬁeld tests [148], suggesting that
the NPY1R is primarily responsible for the anxiolytic-like pheno-
type [149]. The NPY5R has also been reported to increase sponta-
neous GABA release from GABAergic neurons, resulting in an
induction of inhibitory synaptic transmission [150]. NPY5R KO
mice exhibit normal learning and memory in the Morris water
maze and object recognition tests [148]. These results suggest that
the NPY5R display functional redundancy with other NPYRs.
The NPY4R KO mice exhibit reduced anxiety-like and
depression-related behavioral phenotypes, similar to NPY2R KO
mice [144] and in contrast to NPY1R KO mice. A role for the
NPY4R in neurotransmission has not been reported; however, these
studies suggest that NPY4R may also be involved in the regulation
of neurotransmission.
The large number of Y receptors has made it difﬁcult to delin-
eate their individual contributions in physiological processes.
Although recent studies with KO mouse models have begun to
unravel the functions of these receptors, the use of conditional
KO models has facilitated determination of the speciﬁc function
of the individual receptor subtypes in distinct regions of the brain
and should yield further insight into the biological regulation of
these receptors.
2.7. Cannabinoid receptors (CBRs)
The endocannabinoids are a group of neurotransmitters which
are generated from the degradation of membrane phospholipids
[151]. Amongst the various identiﬁed endocannabinoids,
N-arachidonoylethanolamine (AEA) and 2-arachidonoylglycerol
(2-AG) are the major endocannabinoids. They are the physiological
ligands for two GPCR cannabinoid receptors: cannabinoid receptor
1 (CB1R) and cannabinoid receptor 2 (CB2R). Endocannabinoids act
through the CB1R and the CB2R to regulate a variety of physiolog-
ical functions in the CNS and peripheral tissues. The CB1R is
expressed in the brain and peripheral tissues and is the mostabundant GPCR in the brain. It is widely distributed in the cortex,
hippocampus, cerebellum, and basal ganglia [152]. The CB2R is pre-
dominantly expressed in peripheral tissues, but it is also expressed
in the cortex, hippocampus, midbrain and cerebellum [153]. Both
the CB1R and CB2R are expressed in neurons and glia cells. In neu-
rons, both receptors are present in the soma, dendrites, and in axon
terminals. Both the CB1Rs and CB2Rs primarily couple to Gi/o pro-
teins, which leads to the inhibition of adenylyl cyclase and a reduc-
tion in cAMP levels. Activation of CB1Rs, but not CB2Rs, also results
in the inhibition of various VDCCs and the activation of GIRK chan-
nels [154]. The CB1R/CB2R agonist WIN 55,212-2 inhibits EPSCs in
hippocampal slices [155]. This effect can be partially blocked by a
selective CB1R antagonist AM251 and in CB1R KO hippocampal
slices [155]. These results suggest that the CB1R is involved in
the inhibition of EPSCs whereas the role of the CB2R remains to
be deﬁned.
The presynaptic and postsynaptic localization of the CB1Rs sug-
gests that these receptors are involved in the regulation of both
presynaptic and postsynaptic activity. It is well-documented that
activated presynaptic CB1Rs inhibit the release of several neuro-
transmitters, including glutamate, GABA, and dopamine [156].
The NMDARs, at postsynaptic terminals, have been reported to
bind to glutamate to generate a Ca2+ inﬂux, which is crucial for
postsynaptic excitation [157]. Various studies have also demon-
strated NMDAR-mediated EPSCs [158–160]. Interestingly, the
CB1R has been shown to directly interact with the NMDAR NR1
subunit [161], which, in turn, promotes the internalization of both
the CB1R and NR1 subunit, resulting in a reduction in the NMDAR
at the cell surface and the inhibition of EPSCs [161,162]. These
studies suggest that the CB1R modulates NMDAR-mediated
EPSCs. Further studies will be required to determine whether G
protein signaling or additional effector molecules are involved in
the observed effect.
Several studies indicate that the CB1Rs reduce excitatory neu-
rotransmission by modulating both presynaptic and postsynaptic
activities [163–165], suggesting a putative effect on learning and
memory. In this regard, several CB1R agonists, including
A(9)-tetrahydrocannabinol (THC), CP55,940 and WIN55,212-2,
have been shown to impair learning and memory in the
eight-arm radial maze, Morris water maze, and T-maze behav-
ioral paradigms [166–169]. In addition, CB1Rs KO mice display
enhanced learning and memory function in active avoidance
[170] and object recognition behavioral tests [171]. Both para-
digms evaluate hippocampal-dependent cognitive function,
which suggests that the CB1Rs may modulate glutamatergic neu-
rotransmission and EPSCs in vivo. The CB2Rs are less abundant in
the brain relative to CB1Rs. The CB2R KO mice display a
schizophrenia-like phenotype [172], which supports a role for
this receptor in the modulation of neuronal excitation; however,
the function of CB2Rs in neurotransmission requires further
investigation.3. Autoreceptors
Several GPCRs are localized in both presynaptic and postsynap-
tic membrane terminals where they are involved in the regulation
of neurotransmitter release. Interestingly, presynaptic GPCRs also
function as autoreceptors. Autoreceptors are activated by the same
type of neurotransmitter released from the nerve terminal [173].
Consequently, autoreceptors regulate the intrasynaptic feedback
of released neurotransmitters and modulate neurotransmission
between neighboring synapses. A variety of GPCRs have been
reported to function as autoreceptors. For example, 5-HT1A autore-
ceptors negatively regulate the release of 5-HT from serotonergic












mGluR3 Gi/o N.I. [206]
mGluR5 Gq Glutamate release [188,191]







GABABR GABABR Gi/o Glutamate uptake [185]
Adenosine
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A1R Gi/o Glutamate release [185,197]
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CB1R Gi/o Glutamate release [185]
CB2R Gi/o N.I. [207]
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a1AAR Gq Glutamate uptake [208,209]









D2R Gi/o N.I. [210,211]
N.I.: no information.
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tein signaling, thereby inhibiting the ﬁring and activity of the tar-
get neurons [175].
Group II and III mGluRs are predominantly localized in presy-
naptic terminals and have also been shown to function as autore-
ceptors, regulating inhibitory synaptic transmission. The selective
group II mGluR agonists DCG-IV and 2R,4R-4-aminopyrrolidin
e-2,4-dicarboxylate (APDC) reduce neurotransmission in medial
perforant path synapses, but not lateral perforant path synapses
[176], which suggests that group II mGluR autoreceptor function
may be synapse speciﬁc; however, due to lack of speciﬁc mGluR2
and mGluR3 agonists, functional crosstalk between the receptors,
in the absence of autoreceptor activation, cannot be ruled out.
Subcellular distribution of the group III mGluR mGluR7 suggests
that it may also function as an autoreceptor [177]; however,
mGluR subtype-speciﬁc agonists would be required to deﬁnitely
elucidate the potential role as mGluR7 autoreceptors.
Presynaptic GABABRs have also been reported to display autore-
ceptor function. Activation of GABABRs by the selective agonist
baclofen has been shown to induce presynaptic Ca2+ currents
[178], which results in a suppression of GABA release in neurons
of the suprachiasmatic nucleus caused by inhibition of P/Q-type
Ca2+ channels via Gbc dimers [178,179]. These studies conﬁrm
the autoreceptor function of GABABRs, which negatively regulate
GABA release. Electrophysiological studies in GABAB2R KO mice
have shown that the GABABR autoreceptor function is completely
abolished [61], indicating the GABA binding to the remaining
GABAB1Rs in GABAB2R KO mice is not sufﬁcient to preserve autore-
ceptor function. These studies demonstrate that a functional
autoreceptor requires G-protein signaling to regulate neurotrans-
mitter release.
Interestingly, M2Rs, mGlu3Rs, and GABABRs exert a tonic inhi-
bitory effect on neurotransmitter release, probably via direct
actions on the exocytotic machinery [180]. Depolarization has
been suggested to inhibit all three of these receptors [180], which
should lead to enhanced neurotransmitter release. Evidence in
support of this hypothesis has recently been obtained from studies
of neurotransmitter release in which pertussis toxin (PTX)-induced
uncoupling of inhibitory autoreceptors from their G proteins exerts
effects independently of changes in Ca2+ release [181].
Theoretically, this direct voltage control of synaptic function could
contribute to synaptic plasticity [180]. Accordingly, M2R-deﬁcient
mice show behavioral and memory deﬁcits and major changes in
synaptic plasticity at the cellular level [182]; however, the rele-
vance of the M2R voltage dependence in these mice remains to
be ascertained.
4. Astrocytic GPCRs
It is well-documented that astrocytes are involved in the mod-
ulation of synaptic activity. Astrocytes play a pivotal role in the
synthesis of the precursor glutamine for the biosynthesis of the
two major excitatory and inhibitory neurotransmitters: glutamate
and GABA [183]. Glutamine is released from astrocytes through
SN1 transporters and transferred to presynaptic terminals of gluta-
matergic and GABAergic neurons, where it is further processed into
glutamate and GABA. Glutamine can also be converted into gluta-
mate and directly released from astrocytes. The release of gluta-
mate from astrocytes has been shown to be regulated by a
variety of mechanisms including Ca2+-dependent vesicular exocy-
tosis, purinergic P2X7 ion channels, gap junctions, anion channels,
reverse transport and cystine-glutamate antiporters [184].
Astrocytes express a variety of GPCRs which are involved in the
regulation of synaptic activity (for a complete list of astrocytic
GPCRs, see Table 2). In fact, a recent study indicates that astrocyticGPCR activation and G protein-signaling are involved in the regu-
lation of slow and fast glutamate release from astrocytes [185].
Speciﬁcally, the protease-activated receptor 1 (PAR1), a GPCR
which is expressed in most CA1 hippocampal astrocytes, but not
in CA1 pyramidal neurons, couples to two G proteins, Gi/o and Gq.
Selective agonist stimulation of the PAR1 activates both G
protein-signaling cascades, inducing both fast and slow glutamate
release. Conversely, blocking the Gi/o pathway with PTX abolishes
fast, but not slow, glutamate release [185], suggesting that
Gi/o-coupling is required for fast glutamate release in astrocytes.
Further studies indicate that several other Gi/o-coupled GPCRs,
including GABABRs, A1Rs, and CB1Rs, stimulate fast astrocytic glu-
tamate release, opening the glutamate-permeable, two-pore
domain potassium channel TREK-1 [185].
PAR1-activated Gq signaling appears to mediate slow glutamate
release, is Ca2+-dependent, and requires the opening of the
glutamate-permeable, Ca2+-activated anion channel Best1 [185].
In contrast, stimulation of the purinergic P2Y1 receptor (P2Y1R),
another Gq-coupled GPCR, with the non-selective agonist
ADP-analogue 2-methylthioadenosine-50-diphosphate (2MeSADP)
was observed to induce fast glutamate release from astrocytes in
hippocampus [186,187]. Group I mGluRs (mGluR1 and mGluR5)
are also Gq-coupled GPCRs which are expressed in astrocytes
[188]. Stimulation of group I of mGluRs with a non-selective ago-
nist, (S)-3,5-dihydroxyphenylglycine (DHPG), evokes fast gluta-
mate release from astrocytes via exocytosis of glutamate
[189,190]. However, application of 2-methyl-6-(phenylethy
nyl)-pyridine (MPEP), a speciﬁc antagonist selective for mGluR5
reduces glutamate release, suggesting that mGluR5 may modulate
glutamate release in astrocytes [191]. Both 2MeSADP and DHPG
have been reported to induce fast Ca2+ inﬂux, probably through
VDCCs, and Gq-mediated slow Ca2+ release from intracellular Ca2+
stores [192,193]. Collectively, these studies suggest that Ca2+ inﬂux
may mediate fast glutamate release, whereas the Gq-mediated Ca2+
mobilization directs slow glutamate release. The group II mGluR
mGluR3, which couples to Gi/o, has also been reported to be
expressed in astrocytes; however, no study to date has reported
the involvement of mGluR3 in glutamate release from astrocytes.
Collectively, these studies indicate that Gi/o and Gq-coupled
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release.
Astrocytes are also involved control of neurotransmitter uptake
from the extracellular space during neurotransmission, thereby
regulating neurotransmitter concentrations in the synaptic cleft
and the strength and duration of synaptic communication. In the
case of the modulation of excitatory neurotransmitter release,
although some synaptically released glutamate can be taken up
by presynaptic or postsynaptic neuronal transporters or diffuses
away from the synapse, the vast majority of glutamate uptake is
carried out by astrocytic Na+-dependent glutamate transporters
[194]. A recent study demonstrates that activation of astrocytic
Gq-coupled group I mGluRs by a tetanic high-frequency stimulus
[195] in hippocampal slices results in astrocytic glutamate uptake
[196].
In addition to removal of the excitatory neurotransmitter gluta-
mate, astrocytes also regulate the uptake of the inhibitory neuro-
transmitter GABA. The extracellular concentrations of GABA are
controlled of GABA transporters (GATs), which are expressed both
in neurons and astrocytes. A recent study indicates that astrocytic
GABA uptake by GATs is regulated by adenosine activation of
A1R/A2AR heterodimers, which either boost or depress the amount
of GABA available to neurons [197]. Taken together, these studies
indicate that astrocytic transporters and GPCRs regulate the avail-
ability of excitatory and inhibitory neurotransmitters present in
synaptic cleft; however the complex feedback loop of astrocytic
glutamate release and neurotransmitter uptake raises various
interesting questions: what physiological events trigger this pro-
cess? Is this a passive process that is purely dependent on the con-
centration of neurotransmitter at the synapse or is it an active
process used to more precisely control synaptic activity?
5. Conclusions and perspectives
A variety of GPCRs have been shown to modulate neuronal
communication at the synapse. Depending on the localization of
individual GPCRs in neurons, these receptors can function as
autoreceptors to reduce neurotransmitter release, forming intrasy-
naptic or intersynaptic negative feedback loops to regulate neuro-
transmission at presynaptic terminals. Neurotransmitters released
from presynaptic terminals bind to postsynaptic GPCRs and acti-
vate various distinct G protein-signaling pathways. Activation of
G protein-signaling, directly or indirectly, has been shown to mod-
ulate cytoplasmic Ca2+ levels, which leads to membrane hyperpo-
larization and depolarization and contributes to synaptic
excitation or inhibition. GPCR signaling also induces cAMP
response element-binding protein (CREB) activation, leading to
gene transcription and changes in synaptic plasticity. Although
astrocytes play an important role in the regulation of neuronal
communication, the role of astrocytic GPCRs in neuronal commu-
nication is still in the very early stages of investigation. In addition
to G protein-coupling and signaling, the activation of GPCRs can
also induce b-arrestin signaling. The b-arrestins were initially iden-
tiﬁed to mediate the desensitization, internalization, and recycling
of GPCRs. Although they also induce GPCR-stimulated activation of
downstream signaling cascades, reports on a putative role for
b-arrestin-mediated signaling during neurotransmission are very
limited. Furthermore, certain GPCRs have been reported to form
heterodimers, thereby mediating receptor transactivation or
transinhibition. Given the large number of GPCRs which are
expressed in presynaptic and postsynaptic membrane terminals,
it is not surprising that GPCR heterodimers are also localized to
the synapse. These ﬁndings add an additional layer of complexity
to the investigation of the involvement of GPCRs in the regulation
of neuronal communication.Acknowledgements
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